The trend towards more frequent ESA+CD44+ cells in CPA-treated tumors generally held true independent of tumor volume and was more pronounced at higher CPA doses (e.g. 38 mg/kg versus 25 mg/kg; data not shown). The gene discussed is EPCAM; the disease is neoplasm.